[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mild-cognitive-impairment-mci\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mild-cognitive-impairment-mci":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,122,0,25,[9,56,91,116,144,171,199,221,245,274,320,344,382,409,435,461,487,513,540,566,591,621,655,680,703],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100609370","inrad-observational-study-100609370",false,"NCT07213700","InRAD Observational Study","The International Registry for Alzheimer's Disease and Other Dementias (InRAD): An International Registry Observational Study Dedicated to Evaluating Outcomes Data in Alzheimer's Disease","InRAD","Inclusion Criteria:\n\n* Be undergoing diagnostic work-up for Alzheimer's disease (AD), OR\n* Have a confirmed diagnosis of AD (whether currently treated with an AD-specific treatment, or untreated),\n* Be attending an InRAD Center,\n* Have provided informed consent for long-term follow-up\n\nExclusion Criteria:\n\n-Any patient or legal representative who is unable or unwilling to provide a signed informed consent form","ALL",{"count":20,"type":21},50000,"ESTIMATED","10 Years","OBSERVATIONAL","The goal of this international observational study is to evaluate long-term disease outcomes and treatment safety in people with Alzheimer's disease (PwAD), by collecting real-world data from routine clinical practice across global clinical centers.\n\nThe InRAD Registry Observational Study has several aims:\n\n* To collect medical information for many years from a large group of people with Alzheimer's disease. This will be used for research, which will support improved understanding about the disease.\n* To enable researchers to look at the effectiveness, usefulness and safety of treatments for Alzheimer's disease.\n* To enable researchers to answer similar research questions and compare results in many different areas of the world.\n\nPeople with Alzheimer's disease who meet the eligibility criteria and agree to participate in the Study will be asked to visit their doctor (e.g. psychiatrist, geriatrician, or neurologist) at least once a year, or as frequently as is needed for their care. During or after their appointments they may be offered assessments, tests, medications, and treatments as determined by their doctor and their team. This is an observational data collection.",[26,27,28,29],"Alzheimer's Disease(AD)","Mild Cognitive Impairment (MCI)","Subjective Cognitive Decline (SCD)","Non-Alzheimer Degenerative Dementia",[31,32,33,34,35,36,37,38,39,40,41,42],"Alzheimer's disease (AD)","Dementia","Observational study","Real-world data (RWD)","International registry","Cognitive decline","Lecanemab","InRAD Registry","InRAD Foundation","Cognitive screening (MoCA, MMSE)","AD-specific therapies","Clinical staging","RECRUITING","2026-07-01",{"date":46,"type":47},"2026-07-02","ACTUAL",{"date":49,"type":47},"2026-03-30",{"date":51,"type":21},"2036-01",{"name":53,"class":54},"Stichting International Registry for Alzheimer's Disease and other Dementias Foundation","OTHER",6,{"id":57,"slug":58,"hasResults":12,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":12,"sex":18,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":73,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100644702","effects-of-hydroxytyrosol-rich-olive-polyphenol-dietary-supplement-combined-with-mediterranean-diet-adherence-on-the-cognitive-health-of-patients-with-mild-cognitive-impairment-100644702","NCT07672938","Effects of Hydroxytyrosol-Rich Olive Polyphenol Dietary Supplement Combined With Mediterranean Diet Adherence on the Cognitive Health of Patients With Mild Cognitive Impairment","Hydroxytyrosol-Rich Olive Juice Polyphenol and Mediterranean Diet (The MEDIPHENO-HTrial) in Prevention of Cognitive Decline in Community-Dwelling Patients With Mild Cognitive Impairment: A Double-Blind, Placebo-Controlled, 3-Arm, Randomised Controlled Clinical Study","MEDIPHENO-HT","Inclusion Criteria:\n\n* GR-based men and women aged 50 - 85\n* Willingness and ability to conform to the full protocol.\n* Ability to accept and sign the consent form.\n* Presence of a diagnostic classification of Mild Cognitive Impairment according to the National Institute on Aging and Alzheimer's Association (NIA-AA) framework MCI, which corresponds to stage 3 on the pre-dementia range.\n* MoCA score of ≥18 and ≤ 26. Or\n* MMSE (Mini-Mental State Examination) score of ≥26 and ≤ 28.\n* No active suicide ideation based on the Columbia-Suicide Severity Rating Scale.\n* Absence of severe depressive symptomatology based on the Geriatric Depression Scale-15.\n* Not using any laxative drugs for at least three days prior to the screening visit.\n* Information about APOE status\n\nExclusion Criteria:\n\n* Patients with mild, moderate, or severe dementia.\n* Current or recent (within the last 4 weeks) engagement with a strict dietary regime i.e., vegetarian \u002F vegan \u002F ketogenic \u002F paleolithic \u002F high protein \u002F weight loss.\n* Any known issues with blood taking.\n* Any known bleeding disorders.\n* Any known allergy to olives, inability to tolerate gluten or multiple allergies\u002Fintolerances that would significantly limit food intake.\n* Average alcohol use of \\>21 glasses per week for men and \\>14 glasses per week for women (on average for the last six months).\n* History of psychiatric illness including intellectual disability, schizophrenia, bipolar disorder, severe, active depression and alcoholism.\n* Neurologic conditions such as vascular dementia, movement disorders, history of conditions such as anaemia and cancer in the last five years, renal or liver failure, malignant tumours, or organ transplant.\n* Coffee consumption greater than 5 cups per day.\n* Body mass index \\> 35 kg\u002F m2.\n* Not taking a stable dose of statins for at least 3 months before the recruitment visit. Taking antibiotics in the 1 week preceding the recruitment visit.\n* Pregnancy or lactation.\n* Participation in another clinical trial during the last 30 days prior to the recruitment visit.\n* Subject taking supplements that may affect lipoprotein metabolism, \\>1 g of fish oil\u002Fday, antioxidant supplements, cannabidiol (CBD) oil.","50 Years","85 Years",{"count":67,"type":21},141,"INTERVENTIONAL",[70],"NA","Nutrition is an important modifiable risk factor of human cognitive health. Increasing data suggests that certain nutrients or food ingredients, such as plant polyphenols, have the potential to benefit cognitive abilities even in later life. In terms of polyphenols, Hydroxytyrosol (HT) has gained health benefit claims as a potential preventative antioxidant supplementation of neurodegenerative and amyloid-associated diseases while its pharmacological mechanisms suggest protection against cognitive decline. The primary objective of this study will be to evaluate the effects of HT-rich olive juice polyphenol supplementation alongside MeDi adherence compared with placebo alongside MeDi adherence in the prevention of cognitive decline among patients with Mild Cognitive Impairment associated with AD and non-AD pathology.",[27],[74,75,76,77,78,79,80],"Dementia Prevention","Phenolic-rich Nutritional Intervention","Hydroxytyrosol","Mediterranean Diet","Neurodegenerative Biomarkers","Public Health","Clinical Trial","2026-06-28",{"date":83,"type":47},"2026-06-30",{"date":85,"type":47},"2025-03-31",{"date":87,"type":21},"2026-12",{"name":89,"class":54},"Panhellenic Federation of Alzheimer's Disease and Related Disorders",1,{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":18,"minAge":64,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":68,"phases":101,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":90},"100642131","use-of-a-mobile-brain-body-imaging-approach-to-evaluate-the-effects-of-rhythmic-auditory-stimulation-on-gait-and-brain-function-in-alzheimers-disease-100642131","NCT07659964","Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease","Inclusion Criteria:\n\nGeneral Inclusion (both healthy and AD populations):\n\n* Community-dwelling\n* Capable of walking short community distances (approximately 10-15 minutes at a time) without assistance from another person or a device (such as a cane).\n* Able to communicate with researchers\n* Age 50-90 (inclusive)\n\nPopulation-specific Inclusion criteria:\n\n* Healthy -\n\n  * No diagnosis of AD\n* AD population-\n\nCERAD score of \\\u003C1.5 SD from age + education adjusted norms on delayed recall domain or one or more other cognitive domains (i.e. language, attention).\n\nMoCA score between 20-30 MMSE score between 25-30\n\nExclusion Criteria:\n\n* Presence of significant hearing impairment\n* Current orthopedic, neurologic or other medical condition that limits the ability to walk.\n\nThe MOCA, MMSE and CERAD tests will be completed in-person after the participant consents into the study. If the participant is determined to be ineligible based on their performance on these tests (compared to inclusion requirements listed above), they will be informed that they are not eligible for this study and the study visit will be cancelled. They will then be withdrawn from the study; their clinical tests and study documentation will be maintained for the purposes of completeness, but will not be used for any study analyses.",true,"90 Years",{"count":100,"type":21},40,[70],"Alzheimer's Disease (AD) is associated with impairments in both gait and cognition, significantly increasing fall risk. Falls are a leading cause of injury-related disability in older adults, and individuals with AD experience a nearly threefold higher rate of falls compared to neurotypical older adults. There is an urgent need for fall prevention interventions tailored to the unique deficits of individuals with AD. Converging evidence suggests that interventions aiming to reduce fall risk in AD should target both gait and cognition. Rhythmic music interventions, such as Rhythmic Auditory Stimulation (RAS) can harness global brain activation and auditory-motor entrainment to facilitate high-intensity exercise to alleviate AD-related neurocognitive and gait dysfunction. This study aims to assess the neural correlates of gait dysfunction in people with AD, evaluate if baseline neurocognitive impairment is predictive of the effects of RAS, and evaluate RAS benefits for individuals with AD.",[104,27],"Alzheimer Disease (AD)",[106],"RAS","2026-06-17",{"date":109,"type":47},"2026-06-22",{"date":111,"type":47},"2026-06-01",{"date":113,"type":21},"2027-06",{"name":115,"class":54},"Boston University Charles River Campus",{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":18,"minAge":64,"maxAge":65,"enrollmentInfo":123,"targetDuration":4,"studyType":68,"phases":125,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":143},"100595024","phase-2-study-to-evaluate-the-efficacy-and-safety-of-kds2010-in-patients-with-alzheimers-disease-with-mild-cognitive-impairment-and-mild-dementia-due-to-alzheimers-disease-100595024","NCT07027072","Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease","Inclusion Criteria:\n\n* Male and female adults aged ≥50 and ≤85 years at the time of written consent\n* Patients with MCI or mild AD confirmed at screening according to the 2024 diagnostic criteria (APPENDIX 1) of the National Institute on Aging-Alzheimer's Association (NIA-AA)\n* Subjects whose total CDR score (CDR-GS) is 0.5 to 1.0 at screening (however, CDR memory score is ≥0.5)\n* Subjects with a Mini-Mental State Examination (MMSE) score of 21 to 30 at screening\n* Subjects who test positive for amyloid on Positron Emission Tomography (PET) during screening\n* Subjects who have a caregiver capable of providing accurate information about the subject's cognitive and functional abilities and appropriate for the planned assessments in the study, as judged by the investigator\n* Subjects (or their legal representatives) who have voluntarily agreed to participate in this study and have given written consent\n\nExclusion Criteria:\n\n* Cognitive impairment or dementia due to causes other than Alzheimer's disease\n\n  * Vascular dementia, central nervous system infections (e.g., HIV, syphilis, etc.), head trauma, Creutzfeldt-Jakob disease, Pick's disease, Huntington's disease, Parkinson's disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, thyroid disorders, parathyroid disorders, Vitamin B12 deficiency, folic acid deficiency, other metabolic and nutritional deficiencies, etc.\n  * Alcohol or drug abuse, dependence\n* Subjects with cognitive impairment due to hypothyroidism, nutritional deficiencies, Vitamin B12 or folic acid deficiency as assessed during screening\n* Subjects confirmed during screening to have had the following medical history:\n\n  * Malignant tumors within five years prior to screening except for basal cell carcinoma, cutaneous squamous cell carcinoma, thyroid cancer, or carcinoma in situ that has not recurred in over three years and is considered successfully treated by the investigator\n  * History of alcohol or drug abuse within two years prior to screening\n  * Loss of consciousness of unknown cause, or seizure within the past 52 weeks before screening\n  * Unstable and clinically significant cardiovascular diseases despite appropriate treatment (acute coronary syndrome (ACS), tachycardia, clinically significant arrhythmias, cardiomyopathy, angina of at least CSS III, heart failure of NYHA II-IV, or clinically significant valvular heart disease) within 24 weeks before baseline\n  * Severe or active infectious diseases requiring antibiotics or antivirals within four weeks before baseline\n  * A history of stroke involving a major vascular area, transient ischemic attack (TIA), epilepsy, or severe head trauma with loss of consciousness\n  * Hypersensitivity or allergy to any components of the investigational product\n* Subjects confirmed during screening to have had the following accompanying disease:\n\n  * Clinically significant neurological diseases or serious pathological findings affecting cognitive function as confirmed by brain imaging studies within 52 weeks prior to screening, including multiple sclerosis, normal pressure hydrocephalus, brain tumor (however, exceptions are allowed for lesions diagnosed as benign and with a maximum diameter of less than 1 cm), spinal cord infarction, major hemorrhage (defined as having a diameter \\> 1 cm in MRI) or subdural hemorrhage, cerebral vascular malformation, communicating hydrocephalus, inflammatory demyelinating diseases, etc.\n  * Uncontrolled hypertension despite appropriate treatment at screening or baseline (SBP ≥160 mmHg or DBP ≥100 mmHg)\n  * Dizziness or fainting when standing due to orthostatic hypotension that may affect the evaluation according to the judgment of the investigator\n  * Uncontrolled diabetes (HbA1c \\> 9%) during screening, despite appropriate treatment\n  * Bleeding disorders (Platelet \\\u003C50,000\u002Fmm³) during screening, despite appropriate treatment\n  * Patients with severe hepatic impairment (Child-pugh class C) at screening\n  * Following laboratory test values at screening:\n\n    * AST or ALT \\> 2.5 x ULN\n    * total bilirubin \\> 1.5 x ULN (however, in case of Gilbert syndrome, \\> 3.0 mg\u002FdL)\n    * MDRD eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²\n  * QTcF interval \\>450 msecs for male or 470 msecs for female(12-lead ECG) during screening\n  * Gastrointestinal diseases that may affect oral administration or absorption (celiac disease, Crohn's disease, intestinal resection, etc.)\n  * Gastrointestinal diseases, including gastric and duodenal ulcers, that may affect the safety evaluation according to the judgment of the investigator\n  * Psychiatric diagnosis or symptoms that may interfere with the study (uncontrolled major depression, uncontrolled schizophrenia, uncontrolled bipolar affective disorder, etc.), as assessed by the investigator\n  * Positive responses to items 4 or 5 on the Columbia University Suicide Severity Rating Scale (C-SSRS) during screening\n  * Other conditions deemed by the investigator to potentially affect the outcome of the study\n* Subjects who have undergone or require treatment with the following:\n\n  * AD disease-modifying agents (aducanumab, lecanemab, donanemab, gantenerumab, solanezumab, blarcamesine, simufilam, tricaprilin, valiltramiprosate, etc.) within 12 weeks before screening\n  * Medications that may improve cognitive abilities or affect AD treatment (AChEIs, donepezil, galantamine, rivastigmine, tacrine, memantine, etc.) within 12 weeks before screening, except if the subject has been on a stable dose for at least 12 weeks before baseline and maintains the same composition\u002Fdosage\u002Fmethod of administration during the study period\n  * CNS-active drugs or those affecting cognitive function antidepressants other than serotonergic drugs \\[e.g., bupropion\\], sedatives \\[e.g., carbamazepine\\], dopamine antagonists \\[e.g., antipsychotics, metoclopramide\\], amfepramone, mazindol) within 12 weeks before screening\n  * Central anticholinergics and sedating H1-antihistamines within 12 weeks before screening.\n\nHowever, exceptions are allowed for one-time use of the drugs, such as second-generation H1 antihistamines (e.g., cetirizine, levocetirizine, etc.) or peripheral anticholinergics with no central action (e.g., trospium for treating overactive bladder). But the use is prohibited for at least 3 days from the date of cognitive function evaluation.\n\n* Other investigational products or clinical trial devices within four weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)\n* Monoamine oxidase inhibitors (MAOIs) and linezolid within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)\n* Opioids (pethidine, tramadol, tapentadol, etc.) within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)\n* Cyclobenzaprine and St. John's wort within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out)\n* The following serotonergic drugs within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out),\n\n  * selective serotonin (5HT1) agonists\n  * lithium\n  * lamotrigine\n  * ritonavir\n  * dapoxetine\n  * Selective serotonin reuptake inhibitors (SSRIs)\n  * dapoxetine\n  * Serotonin-norepinephrine reuptake inhibitors (SNRIs)\n  * Tricyclic or tetracyclic antidepressants\n  * triazolopyridine antidepressant However, amitriptyline ≤ 50 mg\u002Fday, trazodone ≤ 100 mg\u002Fday, citalopram ≤ 20 mg\u002Fday, and sertraline ≤ 100 mg\u002Fday are allowed without washout.\n* Use of sympathomimetics (ephedrine, methylphenidate, amphetamine, methamphetamine, lisdexamfetamine, etc.) during the screening period\n* Use of Dextromethorphan during the screening period\n* Use of CYP3A4 strong inducer, CYP3A4 strong inhibitor, CYP2D6 strong inducer, and CYP2D6 strong inhibitor during the screening period\n\n  * Inability to undergo MRI or PET scans\n  * Pregnant or breastfeeding women\n  * Fertile women or men who are unwilling to use effective contraception\\* from the date of written consent until 12 weeks after the last administration of the investigational product\n\n    \\*Effective contraception is defined as follows, and at least one method should be used:\n    * Hormonal contraception (oral, injectable, implantable, etc.)\n    * Intrauterine device (IUD) or system (IUS)\n    * Sterilization or surgical procedures (vasectomy, bilateral tubal ligation\u002Fsurgery, hysterectomy)\n    * Dual contraception methods: Simultaneous use of barrier methods (male condoms) with the methods listed above\n    * Absolute abstinence: Total abstinence from sexual intercourse is recognized if the investigator deems the subject's age, occupation, lifestyle, or sexual orientation assures contraception. However, periodic abstinence (calendar method, mucus method, and symptothermal method), withdrawal, and coitus interruptus are not recognized as effective contraception methods.\n  * Other conditions deemed by the investigator to be unsuitable for participation in the study",{"count":124,"type":21},114,[126],"PHASE2","A randomized, double-blind, placebo-controlled, dose-finding Phase 2a clinical trial will be conducted to evaluate the efficacy and safety of KDS2010 in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild dementia due to Alzheimer's disease.\n\nBased on preliminary efficacy observed in the Phase 1 clinical trial, a clinical trial will be conducted in Korea. Eligible patients diagnosed with MCI or mild Alzheimer's disease will be stratified by disease stage (MCI\u002Fmild AD) prior to randomization. Subjects will be randomly assigned in a 1:1:1 ratio to either Treatment Group 1, Treatment Group 2, or the Control Group. The investigational product will be administered orally once daily for a duration of 24 weeks. Approximately 114 subjects will be enrolled, including an estimated 20% dropout rate, with 38 subjects assigned to each group (Treatment Group 1, Treatment Group 2, and Control Group).\n\nThe objectives of the study are as follows:\n\n1. Efficacy Objectives: Efficacy will be evaluated through changes in cognitive function, self-management, and daily living activities before and after administration of KDS2010. Biomarker analysis in plasma and in cerebrospinal fluid (CSF; optional) will also be conducted to explore treatment efficacy.\n2. Safety Objectives: The safety and tolerability will be evaluated after administration of KDS2010.\n3. Exploratory Objectives: The efficacy of Treatment Groups 1 and 2 compared to the Control group will be explored through cognitive endpoints (the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13), and the Mini-Mental State Examination (MMSE)), stratified by demographic information, tauopathy, and ApoE4 genes.\n\nBased on nonclinical and Phase 1 clinical data, KDS2010 will be administered orally once daily at two dose levels: 60 mg and 120 mg.",[27,129,130],"Mild Dementia","Alzheimer's Disease",[132,129,133,134,130],"Mild Cognitive Impairment","KDS2010","MAO-B inhibitor",{"date":109,"type":47},{"date":137,"type":47},"2025-08-06",{"date":139,"type":21},"2027-12-31",{"name":141,"class":142},"NeuroBiogen Co., Ltd","INDUSTRY",8,{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":18,"minAge":151,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":68,"phases":154,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":169,"locationsCount":90},"100641111","the-cognitive-protective-effect-of-vr-based-cognitive-training-in-type-2-diabetes-patients-with-mild-cognitive-impairment-100641111","NCT07650318","The Cognitive Protective Effect of VR-based Cognitive Training in Type 2 Diabetes Patients With Mild Cognitive Impairment","The Cognitive Protective Effect of VR-based Cognitive Training in Type 2 Diabetes Patients With Mild Cognitive Impairment：A Prospective, Randomized, Open-Label, Parallel-Group Pilot Study","Inclusion Criteria:\n\n1. Aged 45-80 years; gender is not restricted;\n2. Participants must meet the diagnostic criteria for diabetes outlined in the \\*Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition)\\*, namely: patients exhibit typical symptoms of diabetes and meet one of the following conditions: 1) HbA1c ≥ 6.5%; 2) Fasting blood glucose ≥7.0 mmol\u002FL. Fasting is defined as no caloric intake for at least 8 hours; 3) 2-hour postprandial blood glucose ≥11.1 mmol\u002FL following an oral glucose tolerance test; 4) Random blood glucose ≥11.1 mmol\u002FL;\n3. Stable glycemic control regimen for 3 months or longer;\n4. Completed a systematic neuropsychological assessment and met the MCI diagnostic criteria outlined in the 2018 American Academy of Neurology Guidelines for Mild Cognitive Impairment, satisfying the following conditions: 1) The patient or a caregiver subjectively perceives a decline in cognitive function; 2) Assessment results indicate impairment in one or more cognitive domains; 3) There is mild impairment in complex instrumental activities of daily living, but the patient maintains independence in basic activities of daily living; 4) Does not yet meet the diagnostic criteria for dementia;\n5. Has an educational level of elementary school or higher and is able to cooperate in completing the assessment, VR training, and various examinations;\n6. Cooperate in undergoing magnetic resonance imaging (MRI) examinations;\n7. Voluntarily participates in this study, signs an informed consent form, and is able to comply with the study protocol requirements to complete follow-up.\n\nExclusion Criteria:\n\n1. Suffering from other dementia-related neurological disorders (such as Alzheimer's disease, Parkinson's disease, etc.) or severe mental illness;\n2. History of central nervous system disorders, including traumatic brain injury, intracranial hemorrhage, acute cerebral infarction, etc.;\n3. Severe sinusitis, space-occupying lesions in the nasopharynx, or congenital disorders affecting the sense of smell,or a history of trauma;\n4. Glaucoma, severe dry eye syndrome, uncorrected strabismus, severe diabetic retinopathy,or severe motion sickness, making the user unable to tolerate VR devices;\n5. History of acute diabetic complications within the past 3 months (diabetic ketoacidosis, hyperglycemic hyperosmolar state, severe hypoglycemia, etc.);\n6. Severe impairment of vital organ function, including cardiac, hepatic, or renal dysfunction;\n7. Pregnant or breastfeeding women, or women planning to become pregnant during the study;\n8. Contraindications for MRI scans, such as the presence of metallic prostheses, pacemakers, cochlear implants, or other metallic implants, or claustrophobia;\n9. Participation in other clinical trials currently or within the past 3 months;\n10. Known or suspected history of allergy to study-related materials;\n11. Currently taking medications intended to improve cognitive function.","45 Years","80 Years",{"count":100,"type":21},[70],"A single-center, prospective, open-label, parallel-group randomized controlled trial is conducted to investigate the cognitive-protective efficacy of a novel, diabetes-specific virtual reality (VR)-based cognitive training system integrated with diet management modules, relative to frequency- and duration-matched traditional paper-and-pencil cognitive training, in adults aged 45-80 years with T2DM and amnestic\u002Fmixed mild cognitive impairment (MCI). A total of 40 eligible participants are randomly assigned 1:1 to either the intervention group (16 weeks of individualized VR training with dynamic difficulty, 2 sessions\u002Fweek, 30-60 minutes\u002Fsession) or the active control group (standardized paper-and-pencil cognitive tasks). All participants maintain stable glucose-lowering regimens for ≥3 months and receive standardized weekly diabetes health education. The primary endpoint is the between-group difference in the change in MoCA total score from baseline to the 16-week follow-up. Secondary endpoints include changes in individual cognitive domains (memory, executive function, attention, processing speed), olfactory threshold\u002Fidentification\u002Frecall, brain structural volumes and resting-state functional connectivity (assessed via 3.0T fMRI), glycemic control (HbA1c, fasting\u002Fpostprandial glucose), lipid profile, body composition, sleep quality, anxiety and depressive symptoms, and diabetes self-management behaviors. The safety and participant adherence to the VR intervention are also systematically monitored.",[157,27],"Type 2 Diabetes Mellitus (T2DM)",[159,160,161,162],"Cognition","Cognitive training","Functional MRI","Virtual reality (VR) technology","2026-06-16",{"date":165,"type":47},"2026-06-18",{"date":111,"type":47},{"date":168,"type":21},"2028-06-01",{"name":170,"class":54},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":97,"sex":18,"minAge":178,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":68,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":90},"100627914","e-align-a-patient-portal-based-intervention-to-align-medications-with-what-matters-most-100627914","NCT07454824","e-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most","e-ALIGN","Inclusion Criteria:\n\n* Patients: Age ≥65, with a diagnosis of MCI or dementia based on ICD-10 codes and ≥1 active CNS-PIM, who are active patient portal users.\n\nCare partners:\n\n* Family or other companions \\>21 years who regularly help the patient with managing medications.\n\nExclusion Criteria:\n\n* As the trial will be based in primary care, individuals residing in long term care facilities or enrolled in hospice will be excluded.","65 Years",{"count":180,"type":21},100,[70],"The overarching goal of this study is to pilot an intervention in which older adults with mild cognitive impairment and dementia and the older adult's care partners are identified in primary care and provided with educational materials through the patient portal to engage the participant in deprescribing. The multicomponent intervention, e-Align, includes delivery of educational information through the patient portal, and a pharmacist-led intervention to align medications with patient and care partner goals and reduce use of central nervous system (CNS) potentially inappropriate medicines (PIM). This work will establish the preliminary data, methods, and partnerships to undertake a multisite embedded pragmatic clinical trial. The resulting triadic-based behavioral intervention will promote patient and care partner engagement, and foster care that aligns with patients' values, and promote improved health and well-being outcomes for people with cognitive impairment and the patient's care partners through deprescribing.",[32,184,27],"Potentially Inappropriate Medication Use",[186,187,188,189,190],"deprescribing","polypharmacy","potentially inappropriate medications","dementia","cognitive impairment","2026-06-15",{"date":163,"type":47},{"date":194,"type":47},"2026-04-15",{"date":196,"type":21},"2027-02-06",{"name":198,"class":54},"Johns Hopkins University",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":18,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":68,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":216,"completionDateStruct":217,"leadSponsor":219,"locationsCount":4},"100641236","the-effects-of-single-baduanjin-and-elastic-band-exercises-on-vswm-in-elderly-individuals-with-mci-100641236","NCT07656480","The Effects of Single Baduanjin and Elastic Band Exercises on VSWM in Elderly Individuals With MCI","The Effects of Single Baduanjin and Elastic Band Exercises on Visuospatial Working Memory in Elderly Individuals With Mild Cognitive Impairment","Inclusion Criteria:\n\n\\- Include the elderly population aged between 60 and 74 years old.\n\n\\- Includes individuals with cognitive impairments. The patients or informants report experiencing memory decline and having certain cognitive dysfunction (MoCA score = 18-25 points).\n\n\\- Including individuals who have controlled diabetes and\u002For cardiovascular diseases to a stable state.\n\n\\- Irregular exercise with the ability to complete a certain amount of physical activities.\n\n\\- Normal vision and hearing.\n\nExclusion Criteria:\n\n\\- Patients with moderate to severe cognitive impairment, mental illness or other neurodegenerative diseases (such as Parkinson's dementia, stroke, frontotemporal degeneration, vascular dementia, Lewy body dementia, etc.).\n\n\\- Long-term or recent use of psychotropic drugs, drugs that affect physical activity ability, cholinergic inhibitors, etc.\n\n\\- Regular exercise habit .\n\n\\- There are serious muscle disorders, or there has been an injury to the lower limbs within the previous six months, making it impossible to stand for a long time or to stand at all.\n\n\\- Severe cardiovascular disease.","60 Years","74 Years",{"count":209,"type":21},60,[70],"Previous studies have confirmed that both acute (single) and long-term various exercise interventions can significantly improve the cognitive function of individuals with MCI. The positive effects of long-term Qigong and elastic band exercises have also been verified. There are relatively few studies on the impact of Qigong and elastic band exercises on working memory. Most studies focusing on working memory mainly target children and college students. The effect of these exercises on the elderly has not been proven, and the improvement mechanism has not been clarified either. This article mainly starts from a single exercise perspective to explore whether a single exercise can improve the VSWM of elderly individuals with MCI. From the perspective of neurophysiology, it also discusses the brain mechanism of single Qigong and elastic band exercises on the working memory of cognitively impaired elderly people, providing reference for future long-term exercise prescriptions for the treatment and prevention of Alzheimer's disease in China.",[27],"NOT_YET_RECRUITING","2026-06-14",{"date":165,"type":47},{"date":44,"type":21},{"date":218,"type":21},"2026-09-14",{"name":220,"class":54},"qiu chen",{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":18,"minAge":228,"maxAge":65,"enrollmentInfo":229,"targetDuration":231,"studyType":23,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":238,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":90},"100641165","an-ai-based-prediction-of-cognitive-capacity-in-older-adults-and-individuals-with-mild-cognitive-impairment-during-virtual-reality-driving-tasks-100641165","NCT07656389","An AI-Based Prediction of Cognitive Capacity in Older Adults and Individuals With Mild Cognitive Impairment During Virtual Reality Driving Tasks","From Eye Movements to Visuomotor Coupling: An AI-Based Prediction of Cognitive Capacity in Older Adults and Individuals With Mild Cognitive Impairment During Virtual Reality Driving Tasks","Inclusion Criteria:\n\n* (1) a score of 23 or higher on the Montreal Cognitive Assessment; (2) a Clinical Dementia Rating score of 0 for cognitively healthy participants or 0.5 for participants with mild cognitive impairment (MCI); (3) healthy young adults aged between 30 and 39 years, and cognitively healthy older adults and participants with MCI aged between 65 and 85 years; (4) right-hand dominance; and (5) adequate visual function to complete VR and eye-tracking tasks, defined as corrected binocular visual acuity of at least 0.5 without severe visual field deficits.\n\nExclusion Criteria:\n\n* (1) the presence or history of major psychiatric disorders or central nervous system diseases; (2) significant ocular diseases, such as untreated cataracts, active retinal diseases, moderate-to-severe or poorly controlled glaucoma, or marked visual field deficits beyond a specified level; (3) epilepsy; and (4) severe dizziness or VR-induced motion sickness.","30 Years",{"count":230,"type":21},192,"12 Months","Driving ability in older adults is essential for independent mobility and social participation, yet declines under high cognitive load or distraction often lead to visual attention failures such as \"look-but-fail-to-see,\" increasing crash risk. Older adults and individuals with mild cognitive impairment (MCI) show impairments in visual attention, executive control, and visuomotor integration, which are not adequately captured by conventional assessments. Virtual reality (VR) integrated with eye-tracking and upper-limb motion analysis enables ecologically valid simulation of driving scenarios and precise quantification of visuomotor behavior. However, current studies are limited by single-scenario designs, unimodal AI models, and insufficient integration of action-related data.\n\nThis study proposes a multi-phase framework: Year 1 develops an eye-movement-based AI model for MCI identification; Year 2 integrates multimodal data in VR driving tasks; and Year 3 establishes an explainable AI system with longitudinal validation. The study aims to advance cognitive assessment and develop a digital tool for early MCI detection and driving risk prediction.",[27,234,235,236,237],"Virtual Reality","Eye Movement Disorder","Multimodal Monitoring","Older Adults",{"date":165,"type":47},{"date":240,"type":21},"2026-06-20",{"date":242,"type":21},"2029-12-31",{"name":244,"class":54},"National Cheng-Kung University Hospital",{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":18,"minAge":178,"maxAge":98,"enrollmentInfo":252,"targetDuration":4,"studyType":68,"phases":254,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":90},"100641674","rtms-combined-with-aerobic-exercise-for-older-adults-with-mild-cognitive-impairment-and-comorbid-depression-100641674","NCT07652775","rTMS Combined With Aerobic Exercise for Older Adults With Mild Cognitive Impairment and Comorbid Depression","Effects of Repetitive Transcranial Magnetic Stimulation Combined With Aerobic Exercise on Cognitive Function, Psychological Health, and Walking Performance in Older Adults With Mild Cognitive Impairment and Comorbid Depression: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 65 to 90 years.\n2. Diagnosed with mild cognitive impairment (MCI) according to established clinical criteria.\n3. Presence of depressive symptoms as determined by clinical assessment and Beck Depression Inventory-II (BDI-II).\n4. Able to communicate and follow study instructions.\n5. Able to ambulate independently with or without an assistive device.\n6. Able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Diagnosis of dementia.\n2. History of epilepsy or seizure disorder.\n3. Presence of metallic implants, pacemakers, cochlear implants, or other contraindications to transcranial magnetic stimulation.\n4. Major neurological disorders, including stroke, Parkinson's disease, traumatic brain injury, or other neurodegenerative diseases.\n5. Severe psychiatric disorders other than depression.\n6. Severe cardiovascular, musculoskeletal, or medical conditions that preclude participation in aerobic exercise.\n7. Severe visual or hearing impairments that interfere with cognitive assessment.\n8. Current participation in another intervention study.",{"count":253,"type":21},45,[70],"This study aims to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) and aerobic exercise on cognitive function and mental health in older adults with mild cognitive impairment (MCI) and comorbid depression. Forty-five participants will be randomly assigned to one of three groups: (1) rTMS alone, (2) rTMS combined with stationary cycling exercise, or (3) sham rTMS combined with stationary cycling exercise. Participants will receive 20 intervention sessions over a 5-week period (4 sessions per week). Outcomes, including cognitive function, depressive symptoms, sleep quality, life satisfaction, self-efficacy, and gait performance, will be assessed at baseline, immediately after completion of the 5-week intervention, and at a 1-month follow-up. The findings may contribute to the development of evidence-based, non-pharmacological interventions for improving cognitive and mental health outcomes in older adults with MCI and comorbid depression.",[27,257],"Depressive Symptoms",[259,260,261,262,263,237,264,265,266],"Repetitive Transcranial Magnetic Stimulation","Aerobic Exercise","Dual-Task Walking","Timed Up and Go","Cognitive Function","Life Satisfaction","Gait Performance","rTMS","2026-06-11",{"date":107,"type":47},{"date":270,"type":47},"2026-03-03",{"date":139,"type":21},{"name":273,"class":54},"Cheng-Hsin General Hospital",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":18,"minAge":282,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":68,"phases":285,"briefSummary":286,"conditions":287,"keywords":289,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":90},"100642202","using-light-therapy-for-mild-cognitive-impairment-100642202","NCT07651787","Using Light Therapy for Mild Cognitive Impairment","Neurovascular and Mitochondrial Mechanisms of Transcranial Photobiomodulation in Vascular Mild Cognitive Impairment","LTMC","Inclusion Criteria:\n\n* Age: 55-95 years of age\n* Clinical Dementia Rating (CDR) equal to 0.5 and\u002For Montreal Cognitive Assessment (MoCA) \\\u003C26 and ≥19\n* Adequate hearing and visual acuity to participate in the examinations\n* English speaker\n* Presence of cerebrovascular pathology confirmed by structural brain imaging method\n\nExclusion Criteria:\n\n* Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer\n* Cerebrovascular accident other than TIA within 60 days prior to Visit 0\n* Diagnosis of amyloid angiopathy\n* Major psychiatric disease, including major depression not controlled on medications, alcohol or drug abuse\n* Neurodegenerative diseases, e.g: Parkinson's, any kind of dementia\n* Patients currently using commercial brain stimulation \u002F neuromodulation device as part of a research study\n* Patients currently take dietary supplements with an expected cerebrovascular benefit such as NAD- or NR-supplementum, L-citrullin, urolithin\n* Unstable medical condition, including uncontrolled diabetes, chronic heart issues, heart failure, chronic obstructive pulmonary disease, hypertension uncontrolled by medication (\\>160\u002F100 mmHg)\n* Any other medical condition or medication which, in the opinion of investigator, would render the patient too unstable to complete the study protocol\n* Severe sensory deficits interfering with the testing","55 Years","95 Years",{"count":100,"type":21},[70],"The goal of this clinical trial is to test whether transcranial photobiomodulation (tPBM), a non-invasive brain stimulation technique using near-infrared light, can improve brain blood flow regulation (neurovascular coupling) and cognitive function in people with mild cognitive impairment (MCI). The main questions it aims to answer are:\n\n* Does tPBM enhance cognitive function and cerebral hemodynamic responses during memory and finger tapping tasks?\n* Does tPBM reduce oxidative stress, inflammation, and mitigate brain cell damage?\n* Is cognitive improvement linked to amyloid status, greater cerebral hemodynamic response, and lower levels of brain inflammation and oxidative stress? Researchers will compare an active tPBM treatment arm to a sham treatment arm to see if tPBM leads to measurable improvements in brain activity and cognitive function compared to no active stimulation.\n\nParticipants will:\n\n* Receive a 20-minute-long active tPBM or sham stimulation session once per day, 6 times per week, for 12 weeks.\n* Complete questionnaires and an iPad-based cognitive testing protocol.\n* Complete memory and motor tasks while their brain activity is measured using non-invasive techniques: simultaneous functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG). Dynamic analysis of the vessels in the eye will also be performed based on eligibility. Transcranial Doppler (TCD) flowmetry is optionally performed.\n* Provide blood samples to test for biomarkers of inflammation, oxidative stress, and brain cell damage.",[27,288],"Amyloid Pathology",[159,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311],"Neurovascular Coupling Mechanism and Cognitive Function","Neurovascular Control","Brain Aging","Brain Activity","Mild Congitive Impairment (MCI)","Amyloid","Transcranial photobiomodulation","Near-infrared spectroscopy","Cerebral hemodynamics","Near-infrared light therapy","NIH Toolbox Cognition Battery","Electroencephalography","Amyloid-positive mild cognitive impairment","Amyloid-negative mild cognitive impairment","Extracellular vesicles","Neuroinflammation","Proinflammatory cytokines","Home-based neuromodulation","Non-invasive brain stimulation","Sham-controlled clinical trial","Randomized clinical trial","photobiomodulation therapy","2026-06-10",{"date":163,"type":47},{"date":315,"type":47},"2025-10-01",{"date":317,"type":21},"2026-12-31",{"name":319,"class":54},"University of Oklahoma",{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":18,"minAge":206,"maxAge":152,"enrollmentInfo":328,"targetDuration":4,"studyType":68,"phases":330,"briefSummary":331,"conditions":332,"keywords":333,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":90},"100642958","digital-lifestyle-coaching-for-alzheimers-disease-prevention-in-apoe4-carriers-100642958","NCT07646054","Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers","Wellderly Brain - Alzheimer's Disease Prevention With Lifestyle Coaching Intervention: A Randomized Clinical Trial","WellderlyBrain","Inclusion Criteria:\n\n* Current 23andMe Research participant with APOE4 positivity genetic variant\n* Age 60 to 80 at time of consent\n* Have access to an Android or Apple iPhone smartphone device and able to download study apps\n* Lives in the United States and able to send and receive US Mail\n* Able and willing to perform a self-administered saliva test at screening\\*for organic outreach only.\n* Able and willing to perform a self-administered finger prick blood collection at three time points throughout the study.\n\nExclusion Criteria:\n\n* Non-English speaking\n* Lives outside of the United States\n* Currently taking or planning on taking GLP-1 medications (Exenatide, Liraglutide, Albiglutide, Dulaglutide, Semaglutide or Tirzepatide) within the next 12 months\n* Established diagnosis of Mild Cognitive Impairment, Alzheimer's Disease or other Neurodegenerative Disease (Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease, Multiple Sclerosis or Frontotemporal Dementia).\n* Current or past Oura Ring user (any Oura Ring use in the last 12 months)",{"count":329,"type":21},1200,[70],"Wellderly Brain is a randomized, direct-to-participant trial evaluating whether a virtually delivered, multidomain lifestyle coaching intervention can favorably impact plasma biomarkers of Alzheimer's disease (AD) in adults aged 60-80 with APOE4 positivity or elevated polygenic risk. Participants are recruited through 23andMe and enrolled via the MyDataHelps platform. Following genetic eligibility screening, 1,200 participants will be randomized to either a digital lifestyle coaching arm (UCardia) or an education-only control arm. The intervention consists of 16 virtual coaching sessions delivered over 52 weeks. All participants will wear an Oura Ring for continuous health monitoring and provide dried blood samples at baseline, 6 months, and 12 months for plasma p-tau217 and proteomic profiling via the NULISAseq CNS Disease Panel. Saliva samples will be collected for epigenetic aging analysis. The study duration is 14-16 months per participant.",[27,104],[334,104],"Alzheimers","2026-06-09",{"date":337,"type":47},"2026-06-12",{"date":339,"type":21},"2026-07-06",{"date":341,"type":21},"2028-12-31",{"name":343,"class":54},"Scripps Translational Science Institute",{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":97,"sex":18,"minAge":178,"maxAge":4,"enrollmentInfo":351,"targetDuration":353,"studyType":23,"phases":4,"briefSummary":354,"conditions":355,"keywords":361,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":143},"100633930","italian-validation-of-the-dna-scale-and-its-correlation-with-neurocognitive-variables-100633930","NCT07533084","Italian Validation of the dNA Scale and Its Correlation With Neurocognitive Variables","Italian Validation of the Dynamic Neurocognitive Adaptation (dNA) Scale and Its Correlation With Neurocognitive Variables","Inclusion Criteria (Stage #1):\n\n* Individuals aged ≥ 65 years residing in Italy;\n* Cognitively healthy individuals (HC);\n* Individuals with subjective memory complaints (SMC);\n* Individuals with mild cognitive impairment (MCI);\n* Individuals with probable Alzheimer's disease (AD).\n\nInclusion criteria (Stage #2 \\& Stage #3):\n\n* Individuals aged ≥ 65 years residing in Italy;\n* Cognitively healthy individuals (HC);\n* Individuals with subjective memory complaints (SMC);\n* Individuals with mild cognitive impairment (MCI);\n* Individuals with probable Alzheimer's disease (AD);\n* Individuals with Alzheimer's disease or other forms of dementia;\n* Individuals suffering from mental disorders clinically diagnosed.\n\nCognitively healthy individuals (HC):\n\n* MMSE score ≥24, or alternatively MoCA score ≥26;\n* No diagnosis of depression, MCI or any form of dementia;\n* Episodic memory performance within the normal range (Wechsler Memory Scale Logical Memory II ≥9 for 16 years of schooling or more; ≥5 for 8-15 years of schooling, ≥3 for 0-7 years of schooling; or alternatively for Prose Memory Test with scores ≥9 for ≥16 years of schooling → ≥5 items in immediate or delayed recall; ≥5 for 8-15 years of schooling → ≥3-4 items in immediate or delayed recall; ≥3 for 0-7 years of schooling → ≥2 items in immediate or delayed recall)\n\nIndividuals with Subjective Memory Complaints (SMC):\n\n* MMSE score ≥24, or alternatively MoCA score ≥26;\n* A significant memory impairment, reported by the subject, a family member, or the clinician;\n* No diagnosis of depression, MCI or any form of dementia;\n* Episodic memory performance within the normal range on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling (≥9 for 16+ years of schooling, ≥5 for 8-15 years of schooling, ≥3 for 0-7 years of schooling) or, alternatively, on the Prose Memory Test (with scores ≥9 for ≥16 years of schooling → ≥5 items in immediate or delayed recall; ≥5 for 8-15 years of schooling → ≥3-4 items in immediate or delayed recall; ≥3 for 0-7 years of schooling → ≥2 items in immediate or delayed recall)\n\nIndividuals with Mild Cognitive Impairment (MCI):\n\n* MMSE score between 19 and 23 inclusive (alternatively MoCA);\n* A decline in memory reported by the subject, a family member, or the clinician;\n* No diagnosis of depression or affected by any form of dementia, with preserved ability in activities of daily living;\n* Objective episodic memory loss on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling.\n\nIndividuals with probable Alzheimer's disease (AD):\n\n* Insidious onset with atypical course: some criteria for probable AD are met, but the onset of symptoms may have been sudden, or there is a lack of objective evidence of progressive cognitive decline;\n* Mixed etiology presentation: All criteria for probable AD are met, with concomitant cerebrovascular disorders, or the presence of features typical of another dementia or the evidence of other neurological disorders or non-neurological comorbidities;\n* A decline in performance compared to the previous level of functioning is evident, as also described by a caregiver (often a family member)\n* Onset with memory disturbances, defined as difficulty learning new information or recalling it;\n* Onset with non-mnemonic symptoms (language symptoms, particularly difficulty finding the correct words; visuospatial symptoms: perceptual deficits characterized by failure to recognize objects, people, or written words; executive symptoms: difficulties with reasoning and critical thinking);\n* MMSE score \\\u003C 23 (alternatively MoCA \\\u003C 25);\n* Objective episodic memory loss on the Wechsler Memory Scale Logical Memory II adjusted for years of schooling.\n\nExclusion criteria (Stage #1):\n\n* Individuals aged \\\u003C 65 years;\n* Individuals not residing in Italy;\n* Individuals with depression or other psychiatric disorders;\n* Individuals with forms of dementia other than Alzheimer's disease.",{"count":352,"type":21},265,"1 Year","The goal of this experimental multicentric intervention study is to validate, in Italian, the dynamic Neurocognitive Adaptation (dNA) Scale, which has already been validated in English, among a healthy elderly population (aged 65 and older) residing in Italy and patients with dementia or Alzheimer's Disease. dNA is a questionnaire designed to assess both current and past levels of engagement in physical, cognitive, creative, and social activities.\n\nThe study aims to recruit a total of 265 participants with mild cognitive impairment, subjective memory complaints, or dementia. These participants will be distributed among the 8 recruitment centers. Neuropsychological data, subjective measures, and MRI data will be collected and analyzed to address the following research questions: 1) Is there a positive correlation between scores on the dNA Scale and cognitive efficiency, as reflected in neuropsychological measures, such as episodic memory and executive functions? 2) Is there a correlation between dNA scores and improved functional connectivity within neural networks, such as the Default Network (DN)?\n\nParticipants recruited at the participating clinical centers will undergo:\n\n* A clinical interview, during which demographic and medical history information will be collected. The dNA Scale will be administered, along with a questionnaire assessing adherence to dietary habits typical of a Mediterranean diet (14-Item Mediterranean Diet Adherence Screener; MEDAS).\n* A neuropsychological assessment, aimed at evaluating general cognitive function with a particular focus on episodic memory and executive functions. The following tests will be administered: Mini-Mental State Examination (MMSE) or, alternatively, Montreal Cognitive Assessment (MoCA); Rey Auditory Verbal Learning Test (RAVLT); Trial Making Test (TMT) Form B; Digit Span Forward and Backward (WAIS or WAIS-III); and the Stroop Test.\n* Self-report questionnaires designed to assess depressive symptoms using the Geriatric Depression Scale (GDS) and anxiety symptoms using the Geriatric Anxiety Scale (GAS) (or alternatively the State-Trait Anxiety Inventory, STAI). Finally, the Cognitive Reserve Index Questionnaire will be administered to estimate Cognitive Reserve (CRIq).\n* Where available, MRI data previously acquired for clinical or diagnostic purposes will be included in the study and analyzed by the principal investigator.",[356,357,27,32,358,359,360],"Active Aging Individuals Aged 65 and Over","Aging","Dementia Alzheimer Type","Subjective Memory Complaints","Probable Alzheimer's Disease",[362,363,364,365,366,367,368,369,370,371,372,373,374],"activities","habits","lifetime protective factors","adaptation","dynamic","neurocognitive","prevention","reserve","resilience","resistance","validation","well-being","aging",{"date":267,"type":47},{"date":377,"type":21},"2026-09",{"date":379,"type":21},"2027-11-27",{"name":381,"class":54},"Neuromed IRCCS",{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":97,"sex":18,"minAge":389,"maxAge":98,"enrollmentInfo":390,"targetDuration":4,"studyType":68,"phases":391,"briefSummary":392,"conditions":393,"keywords":394,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":90},"100626860","enhancing-attention-in-elderly-using-a-brain-computer-interface-100626860","NCT07441122","Enhancing Attention in Elderly Using a Brain-Computer-Interface","Building Cognitive Reserve Through Brain-Computer-Interfaces","Inclusion Criteria:\n\nYounger adults:\n\n* Good general health.\n* Normal or corrected vision.\n* no history of neurological\u002Fpsychiatric disease\n* ability to read and understand English\n* ability to understand information and ability to give a free and informed consent\n\nOlder adults:\n\n* Normal or corrected vision.\n* Self-reports no current diagnosis of dementia.\n* Ability to provide written\u002Felectronic, informed consent.\n\nExclusion Criteria:\n\nYounger Adults:\n\n* Neurological or psychiatric diseases that could be contraindicated for tACS (e.g., personal history of epilepsy\u002Fseizure brain damage, history of fainting, bipolar disorder, schizophrenia, current substance use disorder, etc.).\n* Medications that elevate seizure threshold (e.g., stimulant medication, high dose bupropion).\n* Factors hindering EEG acquisition and tACS delivery (e.g., skin infection, wounds, dermatitis, inability to access the scalp of the participant).\n\nOlder Adults:\n\n* Neurological or psychiatric diseases that could be contraindicated for tACS (e.g., personal history of epilepsy\u002Fseizure brain damage, pacemakers, history of fainting, bipolar disorder, schizophrenia, current substance use disorder, etc.).\n* Medications that elevate seizure threshold (e.g., stimulant medication, high dose bupropion).\n* Factors hindering EEG acquisition and tACS delivery (e.g., skin infection, wounds, dermatitis, inability to access the scalp of the participant).\n* Diagnosis of dementia.\n* Do not have the capacity to provide informed consent.","18 Years",{"count":180,"type":21},[70],"Cognitive reserve refers to the brain's ability to maintain cognitive performance despite age-related changes or neuropathology. Enhancing cognitive reserve is thought to delay cognitive decline and improve functional outcomes in aging and neurodegenerative conditions. Attention and memory-related neural processes are considered key contributors to cognitive reserve, yet it remains unclear whether these neural markers can be deliberately strengthened through targeted training and non-invasive interventions.\n\nThe goal of this clinical study is to investigate whether mindfulness-based meditation and non-invasive brain stimulation can enhance neural markers of attention and memory that serve as proxies for cognitive reserve in cognitively healthy adults and older adults diagnosed with mild cognitive impairment (MCI). Investigators hypothesize that strengthening these neural markers will lead to measurable improvements in cognitive reserve-related functions in both healthy aging and MCI populations.\n\nThis study further hypothesizes that neural markers of attention can be selectively enhanced using an electroencephalography (EEG)-based brain-computer interface (BCI) combined with non-invasive interventions such as mindfulness-based relaxation or neuromodulation. During the study, participants will perform a computerized memory task while their EEG signals are recorded in real time. A BCI will analyze these signals to decode the presence or absence of the P300 event-related potential, a well-established neural marker of attentional control and cognitive resource allocation. Real-time feedback and intervention will be used to modulate these neural processes with the goal of promoting adaptive changes in attention-related brain activity.\n\nBy integrating EEG-based decoding, behavioral training, and non-invasive interventions, this study aims to determine whether targeted modulation of attention-related neural activity can support cognitive reserve in aging and mild cognitive impairment.",[27],[395,396,397,237,398,399,400],"MCI","Memory","Cognitive Decline","Memory Impairment","Cognitive Control","Attention","2026-06-05",{"date":335,"type":47},{"date":404,"type":21},"2026-09-01",{"date":406,"type":21},"2029-02-01",{"name":408,"class":54},"University of Texas at Austin",{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":97,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":418,"conditions":419,"keywords":423,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":90},"100639031","dementia-with-lewy-bodies-clinical-symptoms-biomarkers-and-progression-100639031","NCT07629349","Dementia With Lewy Bodies: Clinical Symptoms, Biomarkers and Progression","Find-DLB","Inclusion Criteria:\n\n* At least one core clinical feature of dementia with Lewy bodies such as visual hallucinations, parkinsonism, cognitive fluctuations, or probable REM sleep behaviour disorder.\n\nExclusion Criteria:\n\n* Causes of cognitive impairment other than those related to dementia or MCI. Current or pass drug use.",{"count":417,"type":21},600,"The goal of this observational study is to improve the detection of dementia with Lewy bodies (DLB) and its prodromal phases, as well as advancing our current understanding of biological mechanisms and therapeutic options. The data is acquired at cognitive clinics in Stockholm (Sweden) and combined with national and international data to increase statistical power, representativeness and replication of results. Participants undergo collection of clinical assessments, neuroimaging and fluid biomarkers.",[420,27,421,422],"Dementia With Lewy Bodies (DLB)","Cognitively Unimpaired","Other Dementias",[424,425,426],"case-control","retrospective","longitudinal","2026-06-04",{"date":401,"type":47},{"date":430,"type":47},"2020-01-01",{"date":432,"type":21},"2031-03-01",{"name":434,"class":54},"Karolinska Institutet",{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":18,"minAge":178,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":68,"phases":443,"briefSummary":444,"conditions":445,"keywords":447,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":4},"100626812","study-of-bedroom-environment-sleep-intervention-at-home-for-older-adults-living-alone-with-memory-concerns-100626812","NCT07440498","Study of Bedroom Environment Sleep Intervention at Home for Older Adults Living Alone With Memory Concerns","A Pilot Feasibility Study of Bedroom Environment Sleep Intervention at Home for Older Adults Living Alone With Memory Concerns","Inclusion Criteria:\n\n* Age 65 years and older\n* Living alone in a private residence or independent living setting ≥5 days\u002Fweek\n* Subjective cognitive decline (Subjective Cognitive Decline Questionnaire MyCog \\> 7\\] OR objective mild cognitive impairment (Montreal Cognitive Assessment \\[MoCA\\] scores between 18-25).\n* Preserved Function (Functional Activity Questionnaire \\\u003C 6)\n* Community-dwelling\n* Self-reported insomnia symptoms\n* Residence in the current home for ≥3 months\n* Expectation to sleep in the designated bedroom on ≥80% of nights during the 8 week protocol\n\nExclusion Criteria:\n\n* Diagnosis of dementia\n* Presence of acute illness or exacerbation of chronic conditions within the past month.\n* Current enrollment in another intervention study",{"count":100,"type":21},[70],"This is an eight-week pilot research study designed to test whether simple changes to the bedroom environment along with brief sleep hygiene strategies, can improve sleep in older adults who live alone, have memory concerns, and experience insomnia symptoms. Older adults may be eligible to participate. The intervention will take 8 weeks, which includes 1-2 in-person visits from the research team at the participant's residence (evaluate the bedroom environment, install participant-agreed bedroom changes, deliver target sleep hygiene strategy) and 2 virtual or telephone calls (support environmental and sleep hygiene strategies) over 8 weeks. Sleep and environment data will be collected at screening\u002Fbaseline, mid-intervention (4-week) and post-intervention (8-week)",[28,27,446],"Insomnia",[448,449,450,451,452,453],"insomnia","home-based intervention","randomized controlled trial","environmental sensors","community-dwelling older adults","sleep",{"date":455,"type":47},"2026-06-08",{"date":457,"type":21},"2026-10",{"date":459,"type":21},"2028-06",{"name":198,"class":54},{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":18,"minAge":282,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":68,"phases":470,"briefSummary":471,"conditions":472,"keywords":474,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":485,"locationsCount":90},"100611100","phase-2-biomarker-based-trial-of-npc-1-for-alzheimers-pathology-100611100","NCT07236190","Biomarker-based Trial of NPC-1 for Alzheimer's Pathology","Early-phase Biomarker-based Trial of NPC-1 for Alzheimer's Disease Pathology","NPC1-AD","Inclusion Criteria:\n\n1. Age 55 and older, male and female;\n2. Subjective Cognitive Impairment or MCI or AD dementia per NIA-AA 2011 criteria;\n3. Clinical Dementia Rating \\\u003C or = to 2 and Mini Mental Status Exam \\> or = to 16;\n4. Modified Hachinski Ischemic Score \\\u003C or = to 4\n5. Geriatric Depression Scale - 15 \\\u003C 6 documenting absence from significant depressive syndromes\n6. Other medications including non-disease modifying for MCI and AD (e.g., acetylcholine esterase inhibitor, N-methyl D-aspartate receptor antagonist) stable \\> or = to 3-months ;\n7. Biomarker evidence of AD pathology: Plasma abeta42\u002F40 ratio \\\u003C or = to 0.12 AND Plasma p-tau217 \\> or = to 0.25 OR Amyloid PET positive (centiloid \\> or = to 20) as part of routine clinical care.\n8. Sufficient vision and hearing to complete all tests\n9. Study partner available with frequent (at least 1 hour\u002Fday or 1 day\u002Fweek) contact with participant to provide collateral information about cognition, daily functioning, adverse events reporting, and support for study drug intake\n10. General health status that will not interfere with the ability to complete the prospective study (these conditions are listed below in the study exclusion list)\n\nExclusion Criteria:\n\n1. CDR \\> 2 MMSE \\\u003C 16;\n2. Significant CNS disease within the last 2 years (i.e., brain tumor, seizure disorder, subdural hematoma, cranial arteritis, cortical stroke);\n3. Alcohol or substance abuse according to DSM-IV criteria within the last 2 years\n4. Major depressive disorder or anxiety within the last year; Schizophrenia, bipolar disorder or other major psychiatric disorder defined by DSM-IV criteria\n5. Abnormal labs indicating potential reversible causes of dementing illness such as vitamin B12 deficiency, thyroid disease, or UTI (documented bacterial colonization is acceptable)\n6. Unstable or significantly symptomatic CVD (e.g. CAD with frequent angina, CHF with dyspnea at rest)\n7. Hypertension: defined as uncontrolled BP \\> 160\u002F100\n8. Clinical symptomatic orthostatic hypotension\n9. Diabetes mellitus that requires insulin injections\n10. Hachinski ischemic score \\> or = to 4\n11. Cancer within the last 5 years, apart from localized prostate cancer (Gleason Grade \\\u003C 3) and non-metastatic skin cancers (melanoma).\n12. Illness that requires \\>1 visit \u002Fmonth to a clinician\n13. Medications and dietary supplements:\n\n    * a. AD disease modifying monoclonal antibody treatment e.g., aducanumab or lecanemab\n    * b. Dietary supplements containing parthenolide or ipriflavone (1-month wash out period prior to enrollment is permitted)\n    * c. CNS active meds that have not been on stable doses for at least 2 months e.g., cimetidine, beta-blockers, and SSRIs\n    * d. Neuroleptics, antiparkinsonian agents, systemic corticosteroids, and narcotic analgesics; in the case where these were used for a self-limited time they must have been discounted for a period of five half-lives prior to baseline visit\n    * e. Over the counter supplements are not by themselves exclusionary, however, participants are asked not to change the dosing regimen over the course of the trial unless medically indicated; the presence and dose of these product are recorded\n14. Participation in any Alzheimer's Disease interventional trial. Participation in other non-AD related trials will be evaluated at the discretion of the investigator\n15. Currently pregnant. Positive pregnancy tests during the course of the trial will be evaluated at the discretion of the investigator.\n\nWomen of Child Bearing Potential (WOCBP)\n\nFor the purposes of this study, women of childbearing potential are defined as all women who are capable of becoming pregnant, unless they meet one of the following criteria:\n\n1. 12-months post-menopausal\n2. Post-hysterectomy\u002Fsurgically sterile\n\nIf a female Participant does not meet either of these criteria they will be considered of childbearing potential and will have a serum pregnancy test performed at Screening, Visit 3 (2 months), Visit 6 (5 months), and Visit 10 (8 months).",{"count":100,"type":21},[126],"This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology",[473,27,28],"Alzheimer Disease",[475,476,477,27,478,479,480],"Open Label","Dietary Supplements","Alzheimer's Disease","Intervention","early phase clinical trial","blood based biomarkers",{"date":455,"type":47},{"date":483,"type":47},"2026-04-01",{"date":113,"type":21},{"name":486,"class":54},"Massachusetts General Hospital",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":97,"sex":18,"minAge":389,"maxAge":65,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":496,"conditions":497,"keywords":498,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":90},"100643723","assessment-of-motor-reserve-in-the-preclinical-stages-of-dementia-100643723","NCT07634055","Assessment of Motor Reserve in the Preclinical Stages of Dementia","Assessment of Motor Reserve in the Preclinical Stages of Dementia.","Inclusion Criteria:\n\n* Patients with Mild Cognitive Impairment (MCI) group\n\n  * Diagnosis of MCI according to the international criteria of the National Institute on Aging-Alzheimer's Association (NIA-AA) (Albert et al., 2011; McKhann et al., 2011).\n  * Age between 40 and 85 years.\n  * Native Italian speaker or sufficient Italian language proficiency to understand the tests.\n  * Signed informed consent provided by the participant or by a legal representative.\n* Healthy subjects group\n\n  * Normal performance on the neuropsychological screening assessment. Age between 40 and 85 years.\n  * Native Italian speaker or sufficient Italian language proficiency to understand the tests.\n  * Signed informed consent.\n\nExclusion Criteria:\n\n* Patients with Mild Cognitive Impairment (MCI) group\n\n  -History of psychiatric or neurological disorders not attributable to MCI. Use of psychotropic medications.\n* Healthy subjects group\n\n  * History of psychiatric or neurological disorders.\n  * Use of psychotropic medications.\n  * Disabling medical comorbidities or medical conditions interfering with motor function.",{"count":495,"type":21},200,"Mild Cognitive Impairment (MCI) is a clinical condition associated with an increased risk of progression to dementia. Although cognitive alterations have traditionally been the main focus of investigation, growing evidence suggests that motor changes may also emerge during the early stages of cognitive decline and may represent potential preclinical indicators of disease.\n\nIn this context, the concept of motor reserve has emerged as a construct of increasing interest, although it remains insufficiently defined. Understanding how motor characteristics may contribute to an individual's ability to compensate for or modulate the effects of cognitive decline could provide new insights into the mechanisms involved in the early stages of dementia.\n\nTherefore, the present monocentric observational study aims to further investigate the concept of motor reserve in healthy individuals and in patients with Mild Cognitive Impairment (MCI) through a multidimensional approach based on clinical, neuropsychological, behavioral, and kinematic assessments. In particular, standardized motor tasks and quantitative movement analyses using a sensor-based medical device will be employed to objectively characterize motor performance.The study plans to recruit approximately 200 participants, including healthy individuals and patients with MCI, enrolled at the Neuropsychology Outpatient Clinic of the Neurology Unit of the University Hospital \"Renato Dulbecco\" in Catanzaro. In the healthy group, the relationship between motor reserve and motor performance will be investigated, while in patients with MCI the relationship between cognitive reserve, motor reserve, clinical and neuropsychological status, and motor performance will be explored.\n\nThe findings of this study may contribute to a broader and more operational definition of motor reserve and support the identification of potential motor biomarkers associated with early cognitive decline. These findings may ultimately contribute to the development of innovative strategies for the early detection and monitoring of conditions at risk of progression to dementia.",[27],[499,500,501,502,503,504],"mci","mild cognitive impairment","Healthy populations","motor reserve","Motor biomarkers","Kinematic assessment","2026-06-03",{"date":455,"type":47},{"date":508,"type":21},"2026-07",{"date":510,"type":21},"2027-07",{"name":512,"class":54},"Istituto per la Ricerca e l'Innovazione Biomedica",{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":389,"maxAge":152,"enrollmentInfo":521,"targetDuration":4,"studyType":68,"phases":523,"briefSummary":524,"conditions":525,"keywords":529,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":534,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":538,"locationsCount":4},"100643698","auto-calibrating-system-for-upper-limb-disability-assessment-neurological-and-occupational-rehabilitation-100643698","NCT07636538","Auto-calibrating System for Upper Limb Disability Assessment, Neurological and Occupational Rehabilitation","Auto-calibrating System for Upper Limb Disability Assessment, Neurological and Occupational Rehabilitation (AS-ULDAR)","ASULDAR","Inclusion Criteria:\n\n* Adult patients aged between 18 and 80 years.\n* Confirmed diagnosis of one of the following neurological conditions: stroke, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), or Mild Cognitive Impairment (MCI).\n* Presence of upper limb motor impairment defined by QuickDASH scores ranging from 20 to 90.\n* Ability to understand and follow the study protocol instructions.\n\nExclusion Criteria:\n\n* Patients with severe psychiatric disorders or cognitive impairments that interfere with the ability to complete cognitive tests and self-assessment scales.\n* Individuals unable to provide informed consent.\n* Subjects with moderate to severe cognitive impairment, defined by an ECAS score lower than 81.92 (ALS patients) or a MoCA score between 18 and 25.\n* Physical conditions significantly limiting upper limb use (e.g., severe concomitant orthopedic disorders affecting shoulder movement).\n* Current or recent participation (within the previous three months) in other rehabilitation programs or interventions that could influence study outcomes.\n* Unstable health conditions that could make device use unsafe or inappropriate, including unstable medical conditions or severe visual impairments.",{"count":522,"type":21},30,[70],"This interventional, multicenter, low-intervention clinical trial aims to evaluate the usability, feasibility, safety, and preliminary clinical impact of a robotic rehabilitation system designed for upper limb rehabilitation in adults with neurological disorders, including Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), post-stroke sequelae, and Mild Cognitive Impairment (MCI).\n\nThe system under study combines a collaborative robot (cobot), inertial sensors, and a graphical user interface capable of supporting reaching exercises, trajectory tracking activities, and cognitive exergames, while also enabling automatic acquisition and visualization of patient performance data.\n\nThe main questions the study aims to answer are:\n\nIs the investigational robotic rehabilitation system usable and feasible in neurological patients undergoing upper limb rehabilitation? Is the use of the device safe for both patients and healthcare operators? Does the addition of robotic-assisted rehabilitation to conventional therapy improve upper limb motor performance, cognitive function, and quality of life compared with conventional rehabilitation alone? Do movement measurements collected by the system correlate with standard clinical assessment scales?\n\nResearchers will compare conventional rehabilitation therapy plus robotic-assisted rehabilitation with conventional rehabilitation therapy alone to evaluate the impact of the device on motor, cognitive, and psychosocial outcomes.\n\nThirty participants will be randomized into two parallel treatment groups. Both groups will receive 12 sessions of conventional rehabilitation therapy lasting 60 minutes each, three times per week. Participants assigned to the experimental group will additionally receive robotic-assisted rehabilitation sessions of up to 30 minutes supervised by rehabilitation staff.\n\nParticipants will undergo:\n\nBaseline collection of demographic and clinical information; Motor, cognitive, and activities of daily living assessments using standardized clinical scales; Conventional rehabilitation therapy sessions; Robotic-assisted upper limb rehabilitation exercises, including task-oriented and trajectory-tracking activities (experimental group only); Monitoring of vital parameters and adverse events during device use; Final evaluation of usability, psychosocial impact, patient satisfaction, motor and cognitive outcomes, and safety.",[526,527,528,27],"Stroke","Amyotrophic Lateral Sclerosis","PARKINSON DISEASE (Disorder)",[530,531,532,533],"Collaborative Robot","Robotic rehabilitation","Neurological disorders","Graphical User Interface",{"date":335,"type":47},{"date":536,"type":21},"2026-06",{"date":457,"type":21},{"name":539,"class":54},"University of Pavia",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":97,"sex":18,"minAge":282,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":550,"conditions":551,"keywords":553,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":90},"100640934","crownlands-observing-progression-with-neurons-study-100640934","NCT07611396","Crownlands Observing Progression With Neurons Study","Crownlands Observing Progression With Neurons I (CROWN-I)","CROWN-I","Inclusion Criteria:\n\n* Informed consent provided by the participant or, where applicable, Legally Authorized Representative (LAR) or other substitute decision-maker where permitted by applicable law, as described in Section 8.2.\n* Male or female, age ≥ 55 years at Screening.\n* Fluency of subject and study partner in English sufficient to complete all cognitive and self-report assessments without interpreter assistance.\n* Adequate visual and auditory acuity (with correction permitted) sufficient to complete neuropsychological testing.\n* Not pregnant or lactating.\n* Medications stable ≥ 4 weeks before screening.\n* GDS-15 \\\u003C 6 (i.e., 0-5 inclusive; no current significant depression).\n* Available study partner who has known the participant for ≥ 12 months, maintains \\~10+ hours per week of in-person or telephone contact, and is willing to attend study visits and complete informant-rated assessments.\n* Willing to complete olfactory brushing, smell testing, and venous blood draw.\n* Willing to commit to baseline and follow-up visits across study duration.\n* In the opinion of the Investigator, able to comply with the protocol-specified visit schedule and procedures for the full study duration.\n\nExclusion Criteria:\n\n* Current or active clinically significant neurological disorder (in the opinion of the Investigator) other than the disorders in the study arms, including but not limited to:\n* Parkinson's disease, dementia with Lewy bodies, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, Huntington's disease, prion disease, multi-infarct dementia, normal pressure hydrocephalus, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, significant head trauma with persistent deficits, or known structural brain abnormalities.\n* Active or unstable major psychiatric illness (DSM-5 schizophrenia spectrum, bipolar I, or severe major depressive disorder with active suicidality) within 6 months prior to Screening; history of schizophrenia at any time.\n* Psychotic features, agitation, or behavioral problems within the last 3 months that could interfere with protocol compliance.\n* Current substance use disorder (DSM-5 moderate or severe), or alcohol use disorder within 24 months prior to Screening.\n* Active malignancy under treatment, or malignancy with expected survival \\\u003C 30 months (excluding non-melanoma skin cancer and localized prostate cancer on active surveillance).\n* Participation in studies collecting neuropsychological measures more than once per year.\n* Presence of previous nasal surgery or other anatomical abnormalities that could interfere with the procedure on both sides of the nose, at the discretion of the clinician administering the Olfactory Brushing.\n* Active respiratory infection or recent history of respiratory infection within the past two weeks.\n* Known allergy or adverse reaction to topical anesthetics or decongestants used in the study (e.g., lidocaine, tetracaine, oxymetazoline).\n* Any other medical or psychiatric condition or lab abnormality that, in the opinion of the Investigator, might preclude participation or render the participant unsuitable for study enrollment.\n\nCognitively Normal (CN) Additional Inclusion Criteria (CN)\n\n* No subjective cognitive complaint reported by participant AND no cognitive -complaint reported by study partner.\n* No current or prior clinical diagnosis of MCI, Alzheimer's disease, or any other dementia, and no current clinical diagnosis of a neurological or neuropsychiatric disease.\n* MMSE score ≥ 27 \u002F 30 at Screening.\n* Global Clinical Dementia Rating (CDR) = 0 at Screening.\n* CDR Sum of Boxes (CDR-SB) = 0 at Screening.\n* Performance within 1.0 standard deviation of demographically adjusted norms on the Rey Auditory Verbal Learning Test (RAVLT) Delayed Recall.\n\nAdditional Exclusion Criteria (CN)\n\n* Current or prior use of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) or memantine for any indication.\n* Current or prior use of anti-amyloid monoclonal antibody disease-modifying therapy (aducanumab, lecanemab, donanemab, or any investigational anti-amyloid mAb).\n\nMild Cognitive Impairment (MCI) Additional Inclusion Criteria (MCI)\n\n* Subjective cognitive complaint reported by participant OR partner-verified memory complaint reported by study partner.\n* MMSE score ≥ 24 and ≤ 30 at Screening.\n* Global CDR = 0.5 at Screening.\n* CDR-SB ≥ 0.5 and \\\u003C 3 at Screening; CDR Memory Box ≥ 0.5.\n* Performance ≥ 1.5 standard deviations below demographically adjusted norms on the RAVLT Delayed Recall (or equivalent episodic memory criterion per the Petersen \u002F NIA-AA MCI framework).\n* Preserved general functional ability such that the participant does not meet criteria for dementia (i.e., does not meet AD criteria in Section 7.3).\n\nAlzheimer's Disease (AD) Additional Inclusion Criteria (AD)\n\n* Confirmed clinical diagnosis of probable Alzheimer's disease by a qualified specialist (cognitive neurologist, geriatric psychiatrist, or equivalent), consistent with NIA-AA 2011 (McKhann et al.) or NIA-AA 2018 Research Framework biological criteria.\n* MMSE score ≥ 16 and ≤ 26 at Screening.\n* Global CDR ≥ 1 at Screening.\n* CDR-SB ≥ 3 at Screening.\n* CDR Memory Box score ≥ 0.5 at Screening.\n* Partner-verified history of progressive cognitive decline of ≥ 6 months duration.\n* Functional impairment consistent with dementia, as documented on the CDR Functional Domains (Community Affairs, Home \\& Hobbies, Personal Care); participant able to complete protocol.",{"count":549,"type":21},160,"The CROWN-I Study is an observational study to learn about molecular features of Alzheimer's disease (AD) and mild cognitive impairment (MCI). The primary objective is to identify the molecular and genetic modules that differentiate patient subtypes and predict progression of AD. Participants will visit clinical sites to donate samples multiple times and perform virtual and in-person clinical assessments.",[552,27],"Alzheimer s Disease",[554,426,555,556,557],"alzheimer's","genetics","olfactory neurons","biomarkers","2026-06-02",{"date":427,"type":47},{"date":561,"type":47},"2026-05-19",{"date":563,"type":21},"2029-05",{"name":565,"class":142},"Crownlands",{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":572,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":18,"minAge":282,"maxAge":152,"enrollmentInfo":574,"targetDuration":4,"studyType":68,"phases":576,"briefSummary":578,"conditions":579,"keywords":580,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":586,"completionDateStruct":587,"leadSponsor":589,"locationsCount":90},"100639116","phase-1-safety-and-tolerability-of-gamma-glutamylcysteine-ggc-oral-supplementation-in-mci-patients-100639116","NCT07583251","Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients","Study For Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients","MCI-GSH","Inclusion Criteria:\n\n1. Memory complaints;\n2. MCI diagnosis\n3. MoCA score between 18-25\n4. Age 55 - 80 years old.\n5. Ability to read and write in English\n\nExclusion Criteria:\n\n1. Subjects with acute head trauma or head injury involving loss of consciousness;\n2. Subjects with a history of cancer;\n3. Subjects with a history of schizophrenia, manic-depressive disorder\n4. Subjects on antioxidant therapy (ashwagandha, gingko biloba, N-acetylcysteine or glutathione)\n5. Subjects on illicit drug (cocaine, heroin, marijuana, or fentanyl) abuse\u002Fdependence;",{"count":575,"type":21},9,[577],"PHASE1","The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg\u002Fday or 800mg\u002Fday or 1200mg\u002Fday) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.",[27],[581,582,395,583],"GSH","GGC","cognitive","2026-05-29",{"date":505,"type":47},{"date":536,"type":21},{"date":588,"type":21},"2027-02",{"name":590,"class":54},"Pravat Mandal",{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":597,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":18,"minAge":178,"maxAge":599,"enrollmentInfo":600,"targetDuration":4,"studyType":68,"phases":601,"briefSummary":602,"conditions":603,"keywords":604,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":617,"leadSponsor":619,"locationsCount":90},"100621109","telehealth-adapted-compensatory-training-and-intervention-for-cognition-100621109","NCT07366346","Telehealth-Adapted Compensatory Training and Intervention for Cognition","Telehealth-Adapted Compensatory Training and Intervention for Cognition for People With Mild Cognitive Impairment","TACTIC","Inclusion Criteria:\n\n* 65 years of age or older, less than 85 years\n* Have the ability to speak and understand English\n* Time and willingness to commit to the completion of this study\n* Availability of a study partner (typically a relative, spouse, offspring, or roommate) for initial and post-intervention testing\n* A global Clinical Dementia Rating scale (CDR) score of 0.5 and cognitive performance of \\\u003C26 on the Montreal Cognitive Assessment (MoCA) or \\\u003C19 on the MoCA-BLIND for categorization of MCI, as determined in the screening appointment.\n\nExclusion Criteria:\n\n* Self-reported diagnosis of dementia or functional impairment that requires assistance\n* Recent changes in medications for memory (i.e., prescribed or changed medications for memory within 30 days)\n* Major psychiatric illness (schizophrenia, current substance dependence, or undertreated depression or anxiety), or 15-item Geriatric Depression Scale (GDS-15) score of eight or higher\n* Hearing, vision, or motor deficits that would interfere with standardized cognitive assessment or participation in study interventions: e.g., inability to hear through headphones (with or without hearing aids). If vision is corrected with lenses to appropriate levels, then participant will be eligible\n* No access to reliable, stable internet, OR\n* Current participation in another cognitive training program or treatment study.","84 Years",{"count":180,"type":21},[70],"The goal of this clinical trial is to develop a five-week virtual cognitive training intervention for people with Mild Cognitive Impairment (MCI) based off an existing eight-week intervention. The main question it aims to answer is:\n\n• Is five weeks of training as good as eight weeks in improving cognition, quality of life, daily functioning, and mood, and in reducing caregiver burden? Researchers will compare five weeks of cognitive training to eight weeks of training to see if the shorter version is as effective as the full training.\n\nParticipants will complete all activities virtually:\n\n* Complete a screening visit with a study partner (typically a family member, roommate, or close friend) to determine eligibility to participate in the study\n* Complete some tests of memory and thinking and some questionnaires\n* Attend weekly two-hour group cognitive training sessions with a trained group leader, for five or eight weeks\n* Redo the questionnaires and tests of memory and thinking immediately after completing the training, and three months after completing the training",[395,132,27],[605,606,500,607,608,609,610,611,612,613,614,189],"cognitive training","compensatory cognitive training","cognitive decline","cognitive intervention","cognitive strategies","group intervention","everyday functioning","cognition","brain health","dementia prevention",{"date":505,"type":47},{"date":584,"type":47},{"date":618,"type":21},"2027-08",{"name":620,"class":54},"University of Florida",{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":627,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":18,"minAge":389,"maxAge":4,"enrollmentInfo":629,"targetDuration":4,"studyType":68,"phases":631,"briefSummary":632,"conditions":633,"keywords":638,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":649,"completionDateStruct":650,"leadSponsor":652,"locationsCount":654},"100639065","evaluation-of-the-impact-of-virtual-park-on-training-motivation-in-adult-patients-100639065","NCT07616050","Evaluation of the Impact of Virtual Park on Training Motivation in Adult Patients","Evaluation of the Impact of a Rehabilitation Intervention Based on Cycling With Virtual Park on Training Motivation in Adult Patients","VP_Adults","Inclusion Criteria:\n\n* Informed consent to the study\n* subjects \\> 18 years and \\\u003C85 years\n* diagnosis of MCI according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders VTh Edition (DSM V TR American Psychological Association 2013)\n* detection of ischemic stroke within 6 months preceding the study, frail elderly subjects (Gobbens RJ et al. 2010)\n* subjects affected by idiopathic Parkinson's disease according to the MDS-PD criteria (Postuma et al., 2015)\n* subjects affected by possible, probable and definite ALS according to the revised El Escorial criteria (Brooks Br, et al. 2000)\n* subjects affected by MS according to the McDonald criteria (2017) with disability measured with the EDSS (Expanded Disability Status Scale) \\\u003C= 8\n* patients with spinal cord injury of different etiology with incomplete spinal cord injury, AIS (ASIA impairment scale) grade C and D, MMSE \\>18\n* subjects naïve to the use of the RV\n* no therapeutic changes or rehabilitation interventions in the month prior to inclusion in the study\n* no ongoing behavioral disorders.\n\nExclusion Criteria:\n\n* Other concomitant neurological pathologies in addition to the one under study\n* presence of visual disturbances that do not allow access to the experimental virtual reality protocol\n* presence of impaired cardiorespiratory function or other organic instabilities that contraindicate ergometer training\n* severe osteoporosis",{"count":630,"type":21},70,[70],"The purpose of this clinical study is to evaluate the feasibility, usability, and motivational impact of VirtualPark, a virtual reality-based dual-task rehabilitation system, in adults with neurological and age-related conditions.\n\nVirtualPark is a virtual reality application designed to deliver cognitive exercises during cycling training using a commercially available ergometer (THERA-Trainer Tigo). The system integrates physical and cognitive tasks in simulated real-life environments.\n\nThe intervention integrates motor and cognitive training tasks targeting domains such as attention, inhibition, working memory, and navigation.\n\nThis is a prospective, multicenter, randomized, cross-over pilot study. It will compare cycling training performed with and without virtual reality. Participants will complete both intervention conditions over a 4-week period separated by a wash-out phase with standard rehabilitation activities. The order of conditions will be randomized.\n\nThe study will assess motivation during rehabilitation training, usability and user experience of the system, as well as exploratory effects on cognitive and motor performance, functional abilities, perceived exertion, and safety.\n\nThe study will enroll adult participants (≥18 years) with conditions such as stroke, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, mild cognitive impairment, spinal cord injury, and frail older adults.",[634,635,527,27,636,637],"Post-stroke","Parkinson Disease","Multiple Sclerosis","Frailty at Older Adults",[639,640,527,132,636,641,642,643,644,645,646],"post-stroke","parkinson disease","spinal cord injury","rehabilitation","dual-task","virtual reality","intrinsic motivation","frail elderly patients with multiple comorbidities","2026-05-25",{"date":584,"type":47},{"date":536,"type":21},{"date":651,"type":21},"2027-01",{"name":653,"class":54},"Marta Mondellini",7,{"id":656,"slug":657,"hasResults":12,"nctId":658,"briefTitle":659,"officialTitle":660,"acronym":4,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":18,"minAge":206,"maxAge":4,"enrollmentInfo":662,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":664,"conditions":665,"keywords":666,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":674,"completionDateStruct":676,"leadSponsor":678,"locationsCount":4},"100637450","validation-of-population-characteristics-and-dosage-prescriptions-for-cognitive-function-intervention-benefits-of-different-doses-of-tai-chi-in-elderly-patients-with-mild-cognitive-impairment-a-real-world-cross-sectional-study-100637450","NCT07608510","Validation of Population Characteristics and Dosage Prescriptions for Cognitive Function Intervention Benefits of Different Doses of Tai Chi in Elderly Patients With Mild Cognitive Impairment: A Real-World Cross-Sectional Study","Real-World External Validation Study on Beneficiary Population Characteristics and Individualized Dose Prescription for Cognitive Improvement of Tai Chi Intervention in Elderly Patients With Mild Cognitive Impairment","Inclusion Criteria:\n\n* 1\\. Presence of mild cognitive impairment, not demented; 2. Age ≥ 60 years old; 3.Regular practice of standardized 24-form simplified Tai Chi for at least 6 months (consistent with the form used in the parent randomized controlled trials \\[RCTs\\]) ; 4.Informed consent and voluntary participation.\n\nExclusion Criteria:\n\n1. Geriatric Depression Scale score ≥ 9 points\n2. Cognitive impairment caused by other reasons, taking drugs, poisoning, etc;\n3. Suffer from severe musculoskeletal system diseases and other contraindications to exercise and are not suitable for Tai Chi training, such as those who suffer from stroke, Parkinson's disease, and have a history of lower limb arthritis, hip and knee joint replacement, etc;\n4. Patients with severe heart, liver, kidney failure, malignant tumors, and other major diseases;\n5. Individuals with visual\u002Fauditory impairments, writing\u002Freading impairments, illiteracy, etc. that affect training and evaluation;\n6. Individuals with uncontrolled hypertension (systolic blood pressure greater than 160mmHg or diastolic blood pressure greater than 100mmHg after medication);\n7. Participating in other experiments that influence this study. -",{"count":663,"type":21},150,"This is a companion real-world external validation study of two pre-registered parent randomized controlled trials (RCTs, protocol IDs: FujianUTCM-1 and FujianUTCM-2). We aim to validate the generalizability and clinical applicability of a pre-developed machine learning prediction model (for Tai Chi intervention cognitive benefit population characteristics and individualized dose prescription) in a real-world community-dwelling population.",[27],[500,667,668,669,670],"taiji","machine learning","External Validation","Real-World Study","2026-05-24",{"date":673,"type":47},"2026-05-27",{"date":675,"type":21},"2026-05-15",{"date":677,"type":21},"2027-03-31",{"name":679,"class":54},"Lidian Chen",{"id":681,"slug":682,"hasResults":12,"nctId":683,"briefTitle":684,"officialTitle":685,"acronym":686,"eligibilityCriteria":687,"healthyVolunteers":12,"sex":18,"minAge":688,"maxAge":65,"enrollmentInfo":689,"targetDuration":4,"studyType":68,"phases":691,"briefSummary":692,"conditions":693,"keywords":694,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":696,"lastUpdatePostDateStruct":697,"startDateStruct":699,"completionDateStruct":700,"leadSponsor":701,"locationsCount":90},"100639024","percepta-for-cognitive-optimization-100639024","NCT07612449","Percepta for Cognitive Optimization","Percepta for Cognitive Optimization: A 6-Month Randomized Controlled Trial With Neurocognitive, Wearable, and Participant-Reported Outcomes in Adults With Mild Cognitive Impairment","PFCO","Inclusion Criteria:\n\n* Demographics: Must be English-speaking and currently residing in the United States.\n* Cognitive Status: Must have self-reported cognitive impairment, defined specifically by a Montreal Cognitive Assessment (MoCA) score of less than 25.\n* Technology Access: Must own an Oura Ring, maintain an active membership throughout the study, and have consistent access to a smartphone for app-based surveys and data syncing.\n* Medical Stability: Must be in good general health and medically stable, with no significant health changes in the three months prior to enrollment.\n* Consent and Compliance: Must provide signed informed consent and demonstrate a willingness to comply with all study procedures, including assessments and lifestyle considerations.\n\nExclusion Criteria:\n\n* Neurological and Psychiatric Disorders: A self-reported diagnosis of dementia, Alzheimer's disease, Parkinson's disease, depressive disorders, bipolar disorder, schizophrenia, epilepsy, multiple sclerosis, or substance use disorder. This also includes a history of stroke, traumatic brain injury (TBI), intracranial hemorrhage, or seizure disorders.\n* Medication Use: Current use of cognitive-affecting medications or supplements, such as donepezil, memantine, methylphenidate, benzodiazepines, antipsychotics, or nootropics.\n* Allergies: Known allergy or sensitivity to cat's claw or oolong tea,. Reproductive Status: Currently pregnant, breastfeeding, or planning to become pregnant within the next 12 months.\n* Genetic Risk: Known carrier of the APOE-4 allele.\n* Recent Study Participation: Enrollment in another clinical trial or intervention study within the past 30 days.","40 Years",{"count":690,"type":21},154,[70],"This Phase 1, randomized, double-blind, placebo-controlled trial evaluates the cognitive and neurophysiological effects of a dietary supplement containing cat's claw (Uncaria tomentosa) bark extract and oolong tea extract, in adults aged 40-85 with self-reported mild cognitive impairment (MCI).\n\nThe study employs a decentralized design leveraging remote monitoring technologies. Participants will self-administer the study supplement or a matched placebo daily for 6 months. The primary outcome is cognitive performance assessed by digital Montreal Cognitive Assessment (MoCA) at baseline, Month 3, and Month 6. Secondary outcomes include objective sleep and autonomic metrics from Oura Ring wearables (heart rate variability, sleep architecture) and self-reported brain health using the Brain Health Index.\n\nAn exploratory sub-study will measure plasma biomarkers of neurodegeneration (pTau-217) at baseline and Month 6 in a subset of participants to explore potential mechanisms of action.\n\nThe study aims to provide preliminary evidence for Percepta's efficacy in improving cognitive function and supporting brain health in individuals with MCI, while evaluating safety and biological plausibility through mechanistic biomarkers.",[27,396],[695,395],"Supplement","2026-05-23",{"date":698,"type":47},"2026-05-28",{"date":111,"type":21},{"date":317,"type":21},{"name":702,"class":54},"Cerebrum DAO Association",{"id":704,"slug":705,"hasResults":12,"nctId":706,"briefTitle":707,"officialTitle":707,"acronym":708,"eligibilityCriteria":709,"healthyVolunteers":97,"sex":18,"minAge":178,"maxAge":4,"enrollmentInfo":710,"targetDuration":4,"studyType":68,"phases":711,"briefSummary":712,"conditions":713,"keywords":714,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":717,"lastUpdatePostDateStruct":718,"startDateStruct":720,"completionDateStruct":722,"leadSponsor":724,"locationsCount":90},"100610270","designing-a-spatial-navigation-intervention-protocol-informed-by-region-specific-brain-activation-for-mild-cognitive-impairment-100610270","NCT07225400","Designing a Spatial Navigation Intervention Protocol Informed by Region-specific Brain Activation for Mild Cognitive Impairment","SNav","Inclusion Criteria:\n\n* Age 65 and older with amnestic mild cognitive impairment (aMCI);\n* Can speak English;\n* Agrees to MoBI recording;\n* Normal or corrected-to-normal vision\u002Faudition;\n* Able to walk unassisted for 10 minutes;\n* Plan to be in the area for next year\n\nExclusion Criteria:\n\n* Dementia (Memory Impairment\u002FAD8 screen);\n* Medical conditions that affect participation such as vertigo and neck pain;\n* Hospitalization in the past six months or plans for surgery affecting participation in the next four months;\n* Mobility limitations solely due to musculoskeletal limitation or pain;\n* Terminal illness with life expectancy less than 12 months;\n* Presence of clinical disorders that overtly alter attention like delirium;\n* Active psychoses or psychiatric symptoms;\n* Living in nursing home;\n* Participation in intervention trial;\n* Standard contraindications to EEG including seizure medication, epilepsy, stroke, traumatic brain injury;\n* Pregnant women",{"count":522,"type":21},[70],"The goal of this one-arm clinical trial is to determine whether participants with mild cognitive impairment (MCI) can successfully navigate a virtual reality (VR) maze. The VR maze is designed as a training tool aimed at improving participants' spatial navigation abilities.\n\nMain Aims:\n\n1. To determine whether at least 70% of older adults enrolled in the study can complete twenty-four 50-minute training sessions over a 4-month period.\n2. To assess whether combining virtual reality with EEG recordings can be used to measure brain activation and changes in brain activation associated with spatial navigation learning.\n\nParticipants will:\n\n1. Walk in an open, unobstructed space while wearing VR goggles.\n2. Explore up to fifty different virtual mazes in sequence and attempt to find their way through each one.",[27],[715,716],"Spatial navigation training","Virtual reality maze design","2026-05-21",{"date":719,"type":47},"2026-05-22",{"date":721,"type":21},"2026-08-01",{"date":723,"type":21},"2027-12-23",{"name":725,"class":54},"Albert Einstein College of Medicine"]